Salspera
Company Snapshot
Salspera is a clinical-stage biotechnology company focused on developing innovative cancer therapies. The company aims to advance its product candidates through rigorous clinical trials, targeting unmet medical needs in oncology. Their key value proposition lies in potentially offering alternative treatment options that deviate from conventional therapies.
Key Financials
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | Not provided | Not provided | Not provided |
| Adjusted Net Loss | -$9.4M | -$9.4M | -$1.4M |
Balance Sheet
Implied Valuation at Midpoint
Based on price range midpoint and most recent fiscal year data.
S-1 Highlights
Market & Competition
The company operates within the biotechnology industry, specifically in the oncology sector. Salspera competes with other biotechnology firms, although specific competitor names are not mentioned in the filing.
Use of Proceeds
Proceeds from the IPO are expected to be utilized for advancing clinical trials, product development, and general corporate purposes.
Key Risk Factors
- ●Salspera faces risks related to patient enrollment in clinical trials, which may be impacted by competition from other companies conducting similar trials.
- ●The company may encounter challenges in obtaining regulatory approvals for their product candidates, which could hinder their ability to commercialize new therapies.
Deal Structure
Reported Broker Availability
Fidelity
Interactive BrokersReported by users or publicly disclosed. Information is for reference only.